Answers are grounded in this paper and cite their sources.
An elevated Ki-67 proliferation index is a known marker of adverse prognosis in several solid and hematological tumors, but its role in Myelodysplastic Syndromes (MDS) remains underexplored. This study aimed to quantify Ki-67 expression across hematopoietic lineages in bone marrow biopsies (BMB) from MDS patients and assess its correlation with clinical features and outcomes. We performed single and double immunohistochemistry for Ki-67 with CD34, CD71, MPO, and Factor VIII on BMB samples from 73 patients diagnosed with MDS or oligoblastic acute myeloid leukemia (AML) at a single center. The cohort had a median age of 70 years, 56% were male, 81% had de novo MDS, and 15% therapy-related MDS. Abnormal karyotypes were present in 32%, and 52% had International Prognostic Scoring System scores ≥ 3.5. Median overall survival (OS) and progression-free survival (PFS) were 2.8 and 2.7 years, respectively. Ki-67 expression upper 10% occurred in 27% of patients. Coexpression of Ki-67 with CD34, MPO, CD71, and Factor VIII was observed in 79%, 63%, 85%, and 16% of cases, respectively. Notably, coexpression Ki-67 with Factor VIII+ correlated with higher blast counts, shorter PFS (HR 3.29), and reduced OS (HR 2.96). Incorporating Ki-67/Factor VIII double labeling improved prognostic accuracy when added to the IPSS-R model. Ki-67 expression in megakaryocytes is a potential independent prognostic marker that requires validation in larger prospective cohorts and may reflect a bone marrow microenvironment dysregulation.
No takes yet. Share an insight, caveat, or question.
Vara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: